



News Release

Source: Patheon Inc.
Website: www.patheon.com

Patheon Inc. Extends its Sterile Filling Capabilities to include the Commercial Supply of Small Scale Specialty products

RESEARCH TRIANGLE PARK, North Carolina, (June 8, 2009) Patheon Inc. (TSX: PTI), a global provider of drug development and manufacturing services to the international pharmaceutical industry, is pleased to announce that its Swindon, UK facility has extended its aseptic vial filling capabilities to include the commercial supply of small scale specialty products. Following recent FDA approval at Swindon, Patheon can now provide clients with a seamless service, where development batches and commercial product can be supplied from the same filling line.

The offering will be especially suited to commercial supply of niche biological and orphan drug products where the annual volumes are small. This new capability is now operating at Patheon's Swindon site for vial sizes ranging from 2mL up to 30mL. In addition, the new technology allows the use of disposable components in place of more costly stainless steel vessels. This provides clients with an efficient filling process that overcomes challenges posed by many large and small molecule sterile products.

Wes Wheeler, President and CEO of Patheon Inc. stated, "We can now produce commercial product from the same production line that is used for Phase II and Phase III clinical batches. This allows clients to commercialize their drugs much faster than would normally be expected."

ABOUT PATHEON INC.

Patheon Inc. (TSX: PTI; www.patheon.com) is a leading global provider of contract development and manufacturing services to the pharmaceutical industry. Patheon prides itself in providing the highest quality products and services to more than 300 pharmaceutical and biotechnology companies. Patheon's services range from preclinical development through the commercial manufacturing of a wide array of dosage forms including parenteral, solid, semi-solid and liquids. Patheon's comprehensive range of fully integrated Pharmaceutical Development Services includes pre-formulation, formulation, analytical development, clinical manufacturing, scale-up and commercialization. Patheon's ability to integrate development and manufacturing services ensures that our customers' projects are delivered on time and meet the high standards of quality that Patheon is known for. Patheon's integrated development and manufacturing network of 10 facilities and 7 development centers, across North America and

Europe, strives to ensure that customer products can be launched timely and confidently anywhere in the world.

Caution Concerning Forward-Looking Statements

This news release may contain forward-looking statements which reflect management's expectations regarding the Company's future growth of operations, performance (both operational and financial) and business prospects and opportunities. These statements are made in the context of the risks and uncertainties that are outlined in the Company's public documents, which can be accessed on our website at www.patheon.com or on SEDAR at www.sedar.com.

Contacts:

Mr. Wes Wheeler
President & Chief Executive Officer
Tel: (919) 226-3200
Email: wes.wheeler@patheon.com

Mr. Norman Barras
Vice President, PDS Europe
Tel: +44(0)7725 423431
Email: norman.barras@patheon.com

Mr. Eric Evans
Chief Financial Officer
Tel: (919) 226-3200
Email: eric.evans@patheon.com